Simon Harrison

Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study

Chhay Lim, Priyadarshini Sinha, Simon J Harrison, Hang Quach, Monica A Slavin, Benjamin W Teh

Journal article  |  2020  |  Mycoses

INTRODUCTION: A multi-centre study to determine the outcomes and risks for invasive fungal disease (IFD) in myeloma (MM) patients ..

Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

Rachel Elizabeth Cooke, Kylie Margaret Quinn, Hang Quach, Simon Harrison, Henry Miles Prince, Rachel Koldej, David Ritchie

Journal article  |  2020  |  Frontiers in Immunology

New diagnoses of multiple myeloma (MM) tend to occur after the age of 60, by which time thymic output is severely reduced. As a co..

Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma

Salvatore Fiorenza, David Routledge, Jenny Collins, Michael Shipton, Simon Harrison, Ashish Bajel, James Cavet, Eleni Tholouli, Jordan Gauthier, David Ritchie

Journal article  |  2020  |  Bone Marrow Transplantation

Candida auris in an Australian health care facility: importance of screening high risk patients

Leon J Worth, Simon J Harrison, Michael Dickinson, Annaliese van Diemen, Jennifer Breen, Susan Harper, Caroline Marshall, Deborah A Williamson, Karin A Thursky, Monica A Slavin

Journal article  |  2020  |  Medical Journal of Australia

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, Paul G Richardson, Anna Marina Liberati, Simon J Harrison, H Miles Prince, Enrique M Ocio, Sylvie Assadourian, Frank Campana, Laure Malinge, Dorothee Semiond, Helgi van de Velde, Kwee Yong

Journal article  |  2020  |  Leukemia

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

Pietro Di Ciaccio, Georgia McCaughan, Judith Trotman, Phoebe Joy Ho, Chan Y Cheah, Shane Gangatharan, Joel Wight, Matthew Ku, Hang Quach, Robin Gasiorowski, Mark N Polizzotto, Henry Miles Prince, Stephen Mulligan, Constantine S Tam, Gareth Gregory, Greg Hapgood, Andrew Spencer, Michael Dickinson, Maya Latimer, Anna Johnston, et al.

Journal article  |  2020  |  Internal Medicine Journal

The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known ..

First in Human Study of In-vivo Imaging of Ex-Vivo Labelled CAR T Cells with Dual PET-MR

R Singla, D Wall, S Anderson, N Zia, J Korte, L Kravets, G McKiernan, J Butler, A Gammilonghi, J Arora, M Wright, B Solomon, RJ Hicks, T Cain, P Darcy, C Cullinane, P Neeson, R Ramanathan, R Shukla, V Bansal, et al.

Conference Proceedings  |  2020  |  Cytotherapy

Levofloxacin prophylaxis in patients with myeloma

Benjamin W Teh, Simon J Harrison, Leon J Worth, Karin A Thursky, Monica A Slavin

Journal article  |  2020  |  The Lancet Oncology

Retinal ischemia due to extramedullary plasmacytomas of the orbit

Arian Lasocki, Emma-Jane Furphy, David A Westerman, Simon Harrison

Journal article  |  2020  |  Journal of Clinical Neuroscience

Visual disturbance is a common complaint in patients with multiple myeloma, both at diagnosis and later in their course, and has a..

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells

Charis E Teh, Jia-Nan Gong, David Segal, Tania Tan, Cassandra J Vandenberg, Pasquale L Fedele, Michael SY Low, George Grigoriadis, Simon J Harrison, Andreas Strasser, Andrew W Roberts, David CS Huang, Garry P Nolan, Daniel HD Gray, Melissa E Ko

Journal article  |  2020  |  Cell Death & Differentiation

Multiple myeloma is an incurable and fatal cancer of immunoglobulin-secreting plasma cells. Most conventional therapies aim to ind..